This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Iroko Pharmaceuticals, LLC
Drug Names(s): IP880, nano-formulated diclofenac, diclinofenac potassium, IP 880, IP-880, Lower Dose Submicron Diclofenac (SoluMatrix)
Description: IP 880 is a SoluMatrix reformulation of diclofenac for use in treating acute pain. The SoluMatrix reformulation platform is a scaleable manufacturing process that can produce nano-sized drug particles which are 10 to 200 times smaller than conventional drug particles.
Iroko is developing IP 880 which was reformulated by iCeutica to reduce the dose of the drug by 20% while retaining or improving the performance of the current commercial drug.
Iroko and Algorithm
In December 2013, Iroko Pharmaceuticals announced that it signed a licensing agreement with Algorithm SAL under which Algorithm will obtain the exclusive rights to market and sell ZORVOLEX (diclofenac) capsules to countries in the Middle East and North Africa (MENA). Under the terms of the agreement, Algorithm will be responsible for achieving regulatory and pricing approval, as well as the marketing and supply of the medication.
Iroko and Farenheit
Iroko Pharmaceuticals announced that it has signed a licensing agreement with PT Pratapa Nirmala (Fahrenheit), under which Fahrenheit will obtain the exclusive rights to market and sell ZORVOLEX (diclofenac) capsules in Indonesia. Under the terms of the agreement, Fahrenheit will be responsible for achieving...See full deal structure in Biomedtracker
Partners: Algorithm S.A.L. PT Pratapa Nirmala-Fahrenheit EMS S.A. Landsteiner Scientific, S.A. Aspen Pharmacare Holdings Limited
Additional information available to subscribers only: